Drug intelligence / Profile preview

EPT-102

Development stage: Preclinical
Lead developer: eptivA Therapeutics

Overview

EPT-102 is an early-stage analgesic candidate currently in the discovery phase, developed by eptivA Therapeutics for the treatment of pain. The company focuses on a 'Personalized Analgesics' approach, utilizing its proprietary Pain Cloud® platform—a SaaS-based R&D tool—to identify specific pain mechanisms and tailor treatments. As of early 2024, technical details regarding EPT-102's molecular target, drug modality (such as small molecule or biologic), and specific mechanism of action remain undisclosed by the developer.

Beyond the preview

Go deeper on EPT-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPT-102.

Explore the full profile